Antoine Saliba

Featured in: Favicon

nature.com Favicon

medscape.com Favicon

mayoclinicproceedings.org Favicon

onlinelibrary.wiley.com

Articles

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort | Blood Cancer Journal

1 month ago | nature.com | Mithun Vinod Shah |Kevin Hung |Anmol Baranwal |Aref Al-Kali |Antoine Saliba |dong chen | +18 more

AbstractThe World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of TP53-mutated (TP53mut) myeloid neoplasm (MN). However, there are substantial differences between the two classifications that may lead to under- or overestimation of the prognostic risk. We retrospectively applied WHO-5 and ICC to 603 MN cases harboring TP53mut (variant allele frequency, VAF ≥ 2%).
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study - Leukemia

Nov 12, 2024 | nature.com | Douglas Tremblay |Clifford M. Csizmar |Courtney DiNardo |Danielle Hammond |Tapan M Kadia |Farhad Ravandi | +10 more

Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy with overlapping features of myelodysplastic neoplasm (MDS) and myeloproliferative neoplasms characterized by peripheral blood monocytosis [1]. There is a predisposition for transformation to acute myeloid leukemia (AML), termed CMML with blast transformation (CMML-BT) [2, 3].

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →